Hypoxia-inducible factors: cancer progression and clinical translation

Hypoxia-inducible factors (HIFs) are master regulators of oxygen homeostasis that match O2 supply and demand for each of the 50 trillion cells in the adult human body. Cancer cells co-opt this homeostatic system to drive cancer progression. HIFs activate the transcription of thousands of genes that mediate angiogenesis, cancer stem cell specification, cell motility, epithelial-mesenchymal transition, extracellular matrix remodeling, glucose and lipid metabolism, immune evasion, invasion, and metastasis. In this Review, the mechanisms and consequences of HIF activation in cancer cells are presented. The current status and future prospects of small-molecule HIF inhibitors for use as cancer therapeutics are discussed.

[1]  M. Koh,et al.  Revisiting the HIF switch in the tumor and its immune microenvironment. , 2021, Trends in cancer.

[2]  G. Semenza,et al.  HIF-1–regulated expression of calreticulin promotes breast tumorigenesis and progression through Wnt/β-catenin pathway activation , 2021, Proceedings of the National Academy of Sciences.

[3]  G. Semenza,et al.  HIF-1 recruits NANOG as a coactivator for TERT gene transcription in hypoxic breast cancer stem cells. , 2021, Cell reports.

[4]  P. Seidel,et al.  Therapeutic Effects of Inhibition of Sphingosine-1-Phosphate Signaling in HIF-2α Inhibitor-Resistant Clear Cell Renal Cell Carcinoma , 2021, Cancers.

[5]  B. Wielockx,et al.  Hypoxia Pathway Proteins and Their Impact on the Blood Vasculature , 2021, International journal of molecular sciences.

[6]  G. Semenza.  Breakthrough Science: Hypoxia-Inducible Factors, Oxygen Sensing, and Disorders of Hematopoiesis. , 2021, Blood.

[7]  G. Semenza,et al.  Histone citrullination by PADI4 is required for HIF-dependent transcriptional responses to hypoxia and tumor vascularization , 2021, Science advances.

[8]  A. Flood,et al.  Correction to: Oxygenation Status of Malignant Tumors vs. Normal Tissues: Critical Evaluation and Updated Data Source Based on Direct Measurements with pO2 Microsensors , 2021, Applied Magnetic Resonance.

[9]  C. C. Wong,et al.  Hypoxia, Metabolic Reprogramming, and Drug Resistance in Liver Cancer , 2021, Cells.

[10]  Lingling Song,et al.  LY-294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K/AKT/HIF-1α pathway , 2021, Molecular medicine reports.

[11]  G. Rabinovich,et al.  Hypoxia Supports Differentiation of Terminally Exhausted CD8 T Cells , 2021, Frontiers in Immunology.

[12]  G. Semenza,et al.  Hypoxia-inducible factor-dependent ADAM12 expression mediates breast cancer invasion and metastasis , 2021, Proceedings of the National Academy of Sciences.

[13]  E. Jonasch,et al.  Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis , 2021, Nature Medicine.

[14]  J. Espinosa,et al.  Multi-omics analysis reveals contextual tumor suppressive and oncogenic gene modules within the acute hypoxic response , 2021, Nature Communications.

[15]  G. Semenza.  Intratumoral Hypoxia and Mechanisms of Immune Evasion Mediated by Hypoxia-Inducible Factors. , 2021, Physiology.

[16]  T. Cox.  The matrix in cancer , 2021, Nature Reviews Cancer.

[17]  Wei Li,et al.  Role of hypoxia inducible factor-1 in cancer stem cells , 2020, Molecular medicine reports.

[18]  J. Zucman‐Rossi,et al.  Hepatocellular carcinoma , 1998, Nature Reviews Disease Primers.

[19]  M. Scartozzi,et al.  Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast? , 2020, Critical reviews in oncology/hematology.

[20]  M. Rauner,et al.  Hypoxia Pathway Proteins are Master Regulators of Erythropoiesis , 2020, International journal of molecular sciences.

[21]  Jieun Seo,et al.  Neddylation blockade induces HIF-1α driven cancer cell migration via upregulation of ZEB1 , 2020, Scientific Reports.

[22]  Z. Werb,et al.  Concepts of extracellular matrix remodelling in tumour progression and metastasis , 2020, Nature Communications.

[23]  G. Semenza,et al.  BIRC2 Expression Impairs Anti-Cancer Immunity and Immunotherapy Efficacy. , 2020, Cell reports.

[24]  G. Semenza.  The Genomics and Genetics of Oxygen Homeostasis. , 2020, Annual review of genomics and human genetics.

[25]  D. Stockton,et al.  Thrombotic risk in congenital erythrocytosis due to up-regulated hypoxia sensing is not associated with elevated hematocrit , 2019, Haematologica.

[26]  U. Günther,et al.  HIF1/2-exerted control over glycolytic gene expression is not functionally relevant for glycolysis in human leukemic stem/progenitor cells , 2019, Cancer & Metabolism.

[27]  G. Berchem,et al.  Improving Cancer Immunotherapy by Targeting the Hypoxic Tumor Microenvironment: New Opportunities and Challenges , 2019, Cells.

[28]  G. Semenza.  Pharmacologic Targeting of Hypoxia-Inducible Factors. , 2019, Annual review of pharmacology and toxicology.

[29]  G. Semenza,et al.  Hypoxia-inducible factors promote breast cancer stem cell specification and maintenance in response to hypoxia or cytotoxic chemotherapy. , 2019, Advances in cancer research.

[30]  S. Shen,et al.  Hypoxia Stimulates the Epithelial–to–Mesenchymal Transition in Lung Cancer Cells Through Accumulation of Nuclear β-Catenin , 2018, AntiCancer Research.

[31]  G. Semenza,et al.  Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment , 2018, Proceedings of the National Academy of Sciences.

[32]  G. Semenza,et al.  Metabolic adaptation of cancer and immune cells mediated by hypoxia-inducible factors. , 2018, Biochimica et biophysica acta. Reviews on cancer.

[33]  C. Zahnow,et al.  Chemotherapy induces enrichment of CD47+/CD73+/PDL1+ immune evasive triple-negative breast cancer cells , 2018, Proceedings of the National Academy of Sciences.

[34]  A. Cheong,et al.  The regulation of transcriptional repression in hypoxia , 2017, Experimental cell research.

[35]  G. Semenza,et al.  Maintenance of redox homeostasis by hypoxia-inducible factors , 2017, Redox biology.

[36]  W. Pavan,et al.  Hypoxia‐induced HIF1α targets in melanocytes reveal a molecular profile associated with poor melanoma prognosis , 2017, Pigment cell & melanoma research.

[37]  G. Semenza,et al.  Chemotherapy-Induced Ca2+ Release Stimulates Breast Cancer Stem Cell Enrichment. , 2017, Cell reports.

[38]  P. Yu,et al.  HIF-1α induces the epithelial-mesenchymal transition in gastric cancer stem cells through the Snail pathway , 2017, Oncotarget.

[39]  G. Semenza,et al.  Hypoxia-Inducible Factors: Master Regulators of Cancer Progression. , 2016, Trends in cancer.

[40]  Maolin Yan,et al.  Hypoxia induces TWIST-activated epithelial-mesenchymal transition and proliferation of pancreatic cancer cells in vitro and in nude mice. , 2016, Cancer letters.

[41]  S. Haferkamp,et al.  LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells. , 2016, Cell metabolism.

[42]  K. Gardner,et al.  Targeting renal cell carcinoma with a HIF-2 antagonist , 2016, Nature.

[43]  Hyejin Cho,et al.  On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models , 2016, Nature.

[44]  Chuanzhao Zhang,et al.  Hypoxia-inducible factors regulate pluripotency factor expression by ZNF217- and ALKBH5-mediated modulation of RNA methylation in breast cancer cells , 2016, Oncotarget.

[45]  G. Reifenberger,et al.  EphrinB2 repression through ZEB2 mediates tumour invasion and anti-angiogenic resistance , 2016, Nature Communications.

[46]  J. Espinosa,et al.  The TIP60 Complex Is a Conserved Coactivator of HIF1A. , 2016, Cell reports.

[47]  E. Rankin,et al.  Hypoxic control of metastasis , 2016, Science.

[48]  S. C. Chafe,et al.  Overcoming Hypoxia-Mediated Tumor Progression: Combinatorial Approaches Targeting pH Regulation, Angiogenesis and Immune Dysfunction , 2016, Front. Cell Dev. Biol..

[49]  ITGA6 is directly regulated by hypoxia-inducible factors and enriches for cancer stem cell activity and invasion in metastatic breast cancer models , 2016, Molecular Cancer.

[50]  Chuanzhao Zhang,et al.  Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m6A-demethylation of NANOG mRNA , 2016, Proceedings of the National Academy of Sciences.

[51]  G. Semenza,et al.  The hypoxic tumor microenvironment: A driving force for breast cancer progression. , 2016, Biochimica et biophysica acta.

[52]  G. Semenza,et al.  HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells , 2015, Proceedings of the National Academy of Sciences.

[53]  R. Schreiber,et al.  Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression , 2015, Cell.

[54]  Chunbo Wang,et al.  SOX2 Promotes the Epithelial to Mesenchymal Transition of Esophageal Squamous Cells by Modulating Slug Expression through the Activation of STAT3/HIF-α Signaling , 2015, International journal of molecular sciences.

[55]  Youngchang Kim,et al.  Structural integration in hypoxia-inducible factors , 2015, Nature.

[56]  G. Semenza,et al.  Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype , 2015, Proceedings of the National Academy of Sciences.

[57]  Meiyan Wu,et al.  HIF-1α Promotes Epithelial-Mesenchymal Transition and Metastasis through Direct Regulation of ZEB1 in Colorectal Cancer , 2015, PloS one.

[58]  A. McCulloch,et al.  HIF1α Represses Cell Stress Pathways to Allow Proliferation of Hypoxic Fetal Cardiomyocytes. , 2015, Developmental cell.

[59]  Pallavi Sontakke,et al.  Hypoxia enhances migration and invasion in glioblastoma by promoting a mesenchymal shift mediated by the HIF1α-ZEB1 axis. , 2015, Cancer letters.

[60]  T. Teknos,et al.  Emerging role of nanog in tumorigenesis and cancer stem cells , 2014, International journal of cancer.

[61]  G. Semenza,et al.  Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells , 2014, Proceedings of the National Academy of Sciences.

[62]  G. Semenza,et al.  Hypoxia-inducible factor 1 mediates TAZ expression and nuclear localization to induce the breast cancer stem cell phenotype , 2014, Oncotarget.

[63]  S. Cao,et al.  Protein expression of hypoxia-inducible factor-1 alpha and hepatocellular carcinoma: a systematic review with meta-analysis. , 2014, Clinics and research in hepatology and gastroenterology.

[64]  Denis Wirtz,et al.  Hypoxia and the extracellular matrix: drivers of tumour metastasis , 2014, Nature Reviews Cancer.

[65]  Jianping Zhang,et al.  HIFs enhance the migratory and neoplastic capacities of hepatocellular carcinoma cells by promoting EMT , 2014, Tumor Biology.

[66]  R. Sun,et al.  Hypoxic regulation of glutamine metabolism through HIF1 and SIAH2 supports lipid synthesis that is necessary for tumor growth. , 2014, Cell metabolism.

[67]  S. McKeown,et al.  Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response. , 2014, The British journal of radiology.

[68]  Wei Zhang,et al.  Iron deficiency modifies gene expression variation induced by augmented hypoxia sensing. , 2014, Blood cells, molecules & diseases.

[69]  J. Erler,et al.  Hypoxia-mediated metastasis. , 2014, Advances in experimental medicine and biology.

[70]  Anton J. Enright,et al.  Integrated analysis of microRNA and mRNA expression and association with HIF binding reveals the complexity of microRNA expression regulation under hypoxia , 2014, Molecular Cancer.

[71]  Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer , 2014, Journal of Molecular Medicine.

[72]  Denis Wirtz,et al.  Hypoxia-inducible factors mediate coordinated RhoA-ROCK1 expression and signaling in breast cancer cells , 2013, Proceedings of the National Academy of Sciences.

[73]  J. Pouysségur,et al.  Disrupting proton dynamics and energy metabolism for cancer therapy , 2013, Nature Reviews Cancer.

[74]  Tim Holland-Letz,et al.  Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay , 2013, Nature Biotechnology.

[75]  P. Leung,et al.  Hypoxia-inducible factor 1 alpha mediates epidermal growth factor-induced down-regulation of E-cadherin expression and cell invasion in human ovarian cancer cells. , 2013, Cancer letters.

[76]  Adrian L Harris,et al.  Glucose utilization via glycogen phosphorylase sustains proliferation and prevents premature senescence in cancer cells. , 2012, Cell metabolism.

[77]  G. Semenza,et al.  Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells , 2012, Proceedings of the National Academy of Sciences.

[78]  G. Semenza,et al.  Hypoxia Regulates CD44 and Its Variant Isoforms through HIF-1α in Triple Negative Breast Cancer , 2012, PloS one.

[79]  Teppei Shimamura,et al.  Dynamic Change of Chromatin Conformation in Response to Hypoxia Enhances the Expression of GLUT3 (SLC2A3) by Cooperative Interaction of Hypoxia-Inducible Factor 1 and KDM3A , 2012, Molecular and Cellular Biology.

[80]  A. Pandiella,et al.  Sox2 expression in breast tumours and activation in breast cancer stem cells , 2012, Oncogene.

[81]  M. Wicha,et al.  Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia , 2012, Proceedings of the National Academy of Sciences.

[82]  G. Semenza,et al.  Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis , 2012, Journal of Molecular Medicine.

[83]  J. Enríquez,et al.  Induction of the mitochondrial NDUFA4L2 protein by HIF-1α decreases oxygen consumption by inhibiting Complex I activity. , 2011, Cell metabolism.

[84]  G. Semenza,et al.  Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation , 2011, Proceedings of the National Academy of Sciences.

[85]  Jiannis Ragoussis,et al.  High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq. , 2011, Blood.

[86]  Fang Yu,et al.  Kruppel-like factor 4 (KLF4) is required for maintenance of breast cancer stem cells and for cell migration and invasion , 2010, Oncogene.

[87]  J. Shay,et al.  Telomeres and telomerase in normal and cancer stem cells , 2010, FEBS letters.

[88]  G. Semenza,et al.  Hypoxia-inducible factor-1-dependent mechanisms of vascularization and vascular remodelling. , 2010, Cardiovascular research.

[89]  Borivoj Vojnovic,et al.  MicroRNA-210 Regulates Mitochondrial Free Radical Response to Hypoxia and Krebs Cycle in Cancer Cells by Targeting Iron Sulfur Cluster Protein ISCU , 2010, PloS one.

[90]  G. Semenza,et al.  Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression , 2010, Proceedings of the National Academy of Sciences.

[91]  Huafeng Zhang,et al.  Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization , 2009, Proceedings of the National Academy of Sciences.

[92]  Joseph Loscalzo,et al.  MicroRNA-210 controls mitochondrial metabolism during hypoxia by repressing the iron-sulfur cluster assembly proteins ISCU1/2. , 2009, Cell metabolism.

[93]  Jeffrey M. Rosen,et al.  Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features , 2009, Proceedings of the National Academy of Sciences.

[94]  John M L Ebos,et al.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. , 2009, Cancer cell.

[95]  Masahiro Inoue,et al.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.

[96]  J. Erler,et al.  Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. , 2009, Cancer cell.

[97]  Erik Sahai,et al.  The actin cytoskeleton in cancer cell motility , 2009, Clinical & Experimental Metastasis.

[98]  Jun O. Liu,et al.  Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth , 2008, Proceedings of the National Academy of Sciences.

[99]  C. Bartram,et al.  Autosomal dominant erythrocytosis and pulmonary arterial hypertension associated with an activating HIF 2 , 2008 .

[100]  S. Vandenberg,et al.  HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. , 2008, Cancer cell.

[101]  R. Plasterk,et al.  The TWIST1 oncogene is a direct target of hypoxia-inducible factor-2α , 2008, Oncogene.

[102]  Kou-Juey Wu,et al.  Direct regulation of TWIST by HIF-1α promotes metastasis , 2008, Nature Cell Biology.

[103]  Michael Höckel,et al.  Detection and characterization of tumor hypoxia using pO2 histography. , 2007, Antioxidants & redox signaling.

[104]  G. Semenza,et al.  HIF-1 mediates the Warburg effect in clear cell renal carcinoma , 2007, Journal of bioenergetics and biomembranes.

[105]  G. Semenza,et al.  HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. , 2007, Cancer cell.

[106]  Gregor Rothe,et al.  Inhibitory effect of tumor cell-derived lactic acid on human T cells. , 2007, Blood.

[107]  G. Semenza,et al.  HIF-1 Regulates Cytochrome Oxidase Subunits to Optimize Efficiency of Respiration in Hypoxic Cells , 2007, Cell.

[108]  R. Cole,et al.  RACK1 Competes with HSP90 for Binding to HIF-1α and is Required for O2-independent and HSP90 Inhibitor-induced Degradation of HIF-1α , 2007 .

[109]  Quynh-Thu Le,et al.  Lysyl oxidase is essential for hypoxia-induced metastasis , 2006, Nature.

[110]  D. Segrè,et al.  Supporting Online Material Materials and Methods Tables S1 and S2 References the Effect of Oxygen on Biochemical Networks and the Evolution of Complex Life , 2022 .

[111]  N. Denko,et al.  HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. , 2006, Cell metabolism.

[112]  G. Semenza,et al.  HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. , 2006, Cell metabolism.

[113]  S. Rafii,et al.  VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche , 2005, Nature.

[114]  Alan Hall,et al.  Rho GTPases: biochemistry and biology. , 2005, Annual review of cell and developmental biology.

[115]  Weiping Zou,et al.  Immunosuppressive networks in the tumour environment and their therapeutic relevance , 2005, Nature Reviews Cancer.

[116]  Karen D. Cowden Dahl,et al.  Hypoxia-inducible factor regulates alphavbeta3 integrin cell surface expression. , 2005, Molecular biology of the cell.

[117]  G. Semenza,et al.  Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. , 2005, Blood.

[118]  C. Shelley,et al.  Leukocyte adhesion during hypoxia is mediated by HIF-1-dependent induction of beta2 integrin gene expression. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[119]  G. Paine-Murrieta,et al.  Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1α , 2004, Molecular Cancer Therapeutics.

[120]  A. Kurtz,et al.  Oxygen tension regulates the expression of a group of procollagen hydroxylases. , 2003, European journal of biochemistry.

[121]  Jinho Kim,et al.  YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. , 2003, Journal of the National Cancer Institute.

[122]  D. Peet,et al.  FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. , 2002, Genes & development.

[123]  G. Semenza,et al.  FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. , 2001 .

[124]  M. Dewhirst,et al.  Comparison of tumor and normal tissue oxygen tension measurements using OxyLite or microelectrodes in rodents. , 2001, American journal of physiology. Heart and circulatory physiology.

[125]  G. Semenza,et al.  Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. , 2001, Cancer research.

[126]  G. Semenza,et al.  Levels of Hypoxia-Inducible Factor-1α During Breast Carcinogenesis , 2001 .

[127]  Till Acker,et al.  Up-regulation of hypoxia-inducible factors HIF-1α and HIF-2α under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function , 2000, Oncogene.

[128]  S. Takahashi,et al.  Hypoxic Induction of Prolyl 4-Hydroxylase α(I) in Cultured Cells* , 2000, The Journal of Biological Chemistry.

[129]  G. Semenza,et al.  Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. , 2000, Cancer research.

[130]  A. Koong,et al.  Loss of PTEN facilitates HIF-1-mediated gene expression. , 2000, Genes & development.

[131]  G. Semenza,et al.  Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. , 2000, Genes & development.

[132]  D A Hilton,et al.  Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. , 1999, Cancer research.

[133]  S. Narumiya,et al.  Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase. , 1999, Science.

[134]  M. Gassmann,et al.  Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. , 1998, Genes & development.

[135]  J. Dick,et al.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.

[136]  G. Semenza,et al.  Hypoxia Response Elements in the Aldolase A, Enolase 1, and Lactate Dehydrogenase A Gene Promoters Contain Essential Binding Sites for Hypoxia-inducible Factor 1* , 1996, The Journal of Biological Chemistry.

[137]  Kozo Kaibuchi,et al.  Regulation of Myosin Phosphatase by Rho and Rho-Associated Kinase (Rho-Kinase) , 1996, Science.

[138]  M. Caligiuri,et al.  A cell initiating human acute myeloid leukaemia after transplantation into SCID mice , 1994, Nature.

[139]  L. H. Gray,et al.  The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy , 1955, British Journal of Cancer.